According to a new study, those with a history of marijuana use are less likely to develop the non-alcoholic fatty liver disease (NAFLD) than those who haven’t used cannabis.
The study, titled “Cannabis consumption and non-alcoholic fatty liver disease: A three years longitudinal study in first-episode non-affective psychosis patients”, was published in the journal Progress in Neuro-Psychopharmacology and Biological Psychiatry.
According to a new study published in the journal JAMA [Journal of the American Medical Association] Pediatrics, marijuana legalization not only doesn’t increase teen usage rates, but it may also actually decrease them.
Those with acute pancreatitis who have a history of marijuana use have “lower age-adjusted, mortality, morbidity, and hospitalization-cost than non-cannabis-exposed patients”, according to a new study.
Senior citizens can enjoy a heightened quality of life thanks to the immense, versatile therapeutics of cannabis. Whether you’re smoking, dabbing, vaping, or using CBD oil and infusions, there is always a way to get potent pain relief and a noticeable lift to your mood. If you’re open cured dried herbs, then there are endless strains of marijuana to choose from, each giving a profoundly different effect. Same goes for the various concentrations of cannabinoids in CBD-oils and extracts, as well as other products like edibles. Getting the medical benefits doesn’t mean that you need to get high, and if you do, there are tons of options for you. Let’s take a close look at how cannabis can help seniors improve their quality of life.
A large majority of hospice professionals support medical marijuana, according to a new study published in The Journal of Palliative Medicine and published online by the U.S. National Institute of Health.
For the study – titled A survey of hospice professional regarding medical cannabis practices – researchers surveyed a nationally representative sample of 310 hospice professionals (primarily nurses) from 40 states. 91% of respondents said that they endorse medical marijuana for hospice patients. In addition, 90% stated that they have fielded questions from patients regarding medical marijuana, and 73% said that they’ve had a patient who has used it.
The study states that “[R]egardless of legal status, hospice staff overwhelmingly support patient access to MC (medical cannabis). Those who practice in states where MC is not yet legal wish that it was.”
According to a new study, drivers who test positive for THC do not possess a significantly increased risk of being responsible for a non-fatal motor vehicle accident.
For the study, researchers at the University of British Columbia compared the likelihood of crash responsibility in drivers testing positive for THC and/or other substances as compared to drug-free drivers over a six-year period (2010 to 2016).
As reported on by NORML, the state found that, “In this multi-site observational study of non-fatally injured drivers, we found no increase in crash risk, after adjustment for age, sex, and use of other impairing substances, in drivers with THC<5ng/ml. For drivers with THC>5ngml there may be an increased risk of crash responsibility, but this result was statistically non-significant and further study is required. … Our findings … suggest that the impact of cannabis on road safety is relatively small at present time.”
According to a new study published by the journal Preventive Medicine, medical marijuana legalization is associated with reduced opioid prescription rates.
The study, titled “Association between cannabis laws and opioid prescriptions among privately insured adults in the US,” analyzed how different cannabis laws influenced the rate of opioid prescriptions among adults from different age groups in 2016.
According to High Times, who first reported on the study, researchers examined the relationships between a few different variables. First, age, breaking it up into five groups, 18-25, 26-35, 36-45, 46-55, and 56-64 years. Second, changes in state cannabis law, whether decriminalization, medical legalization, or adult-use legalization. And third, the pattern and rate of opioid prescriptions, broken down into greater than 30-day and greater than 90-day prescriptions.
Marijuana use is directly associated with both symptom mitigation and a reduction in prescription drugs in those with MS (multiple sclerosis), according to a new study published in the journal Neurology and epublished by the U.S. National Institute of Health.
“The purpose of this study was to investigate the role of medical cannabis in improving symptomatology in patients diagnosed with multiple sclerosis (MS)”, states the study’s abstract. “We also sought to collect data on other pertinent outcomes related to the use of cannabis to enhance understanding of the potential benefits this complementary therapy offers.”
For the study, “A retrospective chart review of 77 patients diagnosed with multiple sclerosis participating in treatment with medical cannabis for symptom management was conducted (F=53, M=24, Mean Age=49±12). A variety of objective and subjective variables that pertain to alleviation of MS symptoms were collected from each of the first four appointments following initiation of medical cannabis.” In addition, “A cross-sectional review of self-rating scales completed by patients was also conducted to determine gross changes in mental health.”
According to a study published in the journal Digestive Diseases and Sciences, marijuana consumers with Crohn’s disease who are seeking hospitalization possess fewer disease-related complications compared to those who don’t use cannabis.
For the study a team of investigators from the John H. Stroger Hospital in Chicago, the SUNY Downstate Medical Centre in New York City, and the Digestive Disease Institute in Cleveland assessed the relationship between cannabis use and the prevalence of Crohn’s disease-related complications and clinical outcomes in a nationwide cohort of hospitalized patients.
According to a NORML news release, authors reported that patients with a history of cannabis use possessed fewer complications and experienced better clinical outcomes as compared to abstainers.